source
- AstraZeneca withdraws EU filing for monoclonal antibody targeting amyloidosis subsetAstraZeneca has announced that it is pulling its European marketing application for a monoclonal antibody intended for a specific subgroup of amyloidosis patients. The decision follows earlier fail…
- Doctors question Boston Scientific's Watchman marketing after FDA approvalBoston Scientific's Watchman cardiac implant has been placed in more than 800,000 patients worldwide. The device eventually secured FDA approval after a protracted review, but the clearance was li…